Interlink provides Januvia pre-launch med ed

Interlink Healthcare Communications will provide pre-launch medical education for Merck's Januvia (sitagliptin), a DPP-4 inhibitor for treating type II diabetes. Januvia is expected to be decided on by the FDA in October.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions